Status:

COMPLETED

52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or Spine

Lead Sponsor:

Novartis

Conditions:

Osteoarthritis

Eligibility:

All Genders

40+ years

Phase:

PHASE3

Brief Summary

This trial will compare the retention on treatment (based on the rate of patients staying on treatment for 1 year) of patients suffering from primary osteoarthritis using two different doses of lumira...

Eligibility Criteria

Inclusion

  • Primary osteoarthritis in the hip, knee, hand, or spine
  • Requiring NSAID therapy

Exclusion

  • Secondary OA with history and/ or any evidence of the following diseases: rheumatoid arthritis, uncontrolled gout, inflammatory joint disease, ochronosis, acromegaly, hemochromatosis, Wilson's disease, primary osteochondromatosis, heritable disorders (e.g. hypermobility), collagen gene mutations, primary fibromyalgia (secondary fibromyalgia is allowed if in the opinion of the investigator it will not interfere with the patient's OA pain assessment), and systemic lupus erythematosus
  • History and/ or any evidence of the following diseases in the target joint: septic arthritis, gout, recurrent episodes of pseudogout, Paget's disease of the bone, and articular fracture. If the patient has history of these conditions, then patient should only be excluded if the target joint is affected.
  • History of severe adverse reactions of any kind under lumiracoxib or celecoxib treatment.
  • Other protocol-defined inclusion/exclusion criteria may apply.

Key Trial Info

Start Date :

September 1 2004

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

3036 Patients enrolled

Trial Details

Trial ID

NCT00145301

Start Date

September 1 2004

Last Update

May 21 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Novartis

Nuremberg, Germany